Pan-mutant-IDH1 Inhibitor BAY1436032 is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia in Vivo

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 Feb 25

PMID 28232670

Citations 62

Authors

A Chaturvedi

L Herbst

S Pusch

L Klett

R Goparaju

D Stichel

S Kaulfuss

O Panknin

K Zimmermann

L Toschi

R Neuhaus

A Haegebarth

H Rehwinkel

H Hess-Stumpp

M Bauser

T Bochtler

E A Struys

A Sharma

A Bakkali

R Geffers

M M Araujo-Cruz

F Thol

R Gabdoulline

A Ganser

A D Ho

A Von Deimling

K Rippe

M Heuser

A Kramer

Affiliations

Soon will be listed here.

Abstract

Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 inhibitor, both in vitro and in vivo. BAY1436032 specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells carrying IDH1R132H, IDH1R132C, IDH1R132G, IDH1R132L and IDH1R132S mutations. In addition, the compound impacts on DNA methylation and attenuates histone hypermethylation. Oral administration of BAY1436032 led to leukemic blast clearance, myeloid differentiation, depletion of leukemic stem cells and prolonged survival in two independent patient-derived xenograft IDH1 mutant AML mouse models. Together, BAY1436032 is highly effective against all major types of IDH1 mutant AML.

Citing Articles

Energy metabolism in health and diseases.

Liu H, Wang S, Wang J, Guo X, Song Y, Fu K Signal Transduct Target Ther. 2025; 10(1):69.

PMID: 39966374 PMC: 11836267. DOI: 10.1038/s41392-025-02141-x.

Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials.

Cai Z, Yang H, Yu Z, Su J, Zhang J, Ye Z World J Surg Oncol. 2024; 22(1):295.

PMID: 39511636 PMC: 11546319. DOI: 10.1186/s12957-024-03579-z.

Biostructural, biochemical and biophysical studies of mutant IDH1.

McCoy M, Lu J, Richard Miller F, Soisson S, Lam M, Fischer C Nat Commun. 2024; 15(1):7877.

PMID: 39251618 PMC: 11385386. DOI: 10.1038/s41467-024-51692-0.

The Alliance Between the German Cancer Research Center and Bayer: A Retrospective of an Innovative Collaboration Model.

Zuccotti A, Carretero R, Hess-Stumpp H Handb Exp Pharmacol. 2024; 286:83-95.

PMID: 39177747 DOI: 10.1007/164_2024_726.

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia.

Sharma P, Borthakur G Cancer Drug Resist. 2023; 6(3):567-589.

PMID: 37842232 PMC: 10571063. DOI: 10.20517/cdr.2023.12.

References

Davis M, Gross S, Shen M, Straley K, Pragani R, Lea W . Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem. 2014; 289(20):13717-25. PMC: 4022846. DOI: 10.1074/jbc.M113.511030. View

Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

Thol F, Weissinger E, Krauter J, Wagner K, Damm F, Wichmann M . IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010; 95(10):1668-74. PMC: 2948091. DOI: 10.3324/haematol.2010.025494. View

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N . Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am J Pathol. 2011; 178(3):1395-402. PMC: 3069821. DOI: 10.1016/j.ajpath.2010.12.011. View

Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D . Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010; 116(4):614-6. DOI: 10.1182/blood-2010-03-272146. View

Medeiros B, Fathi A, DiNardo C, Pollyea D, Chan S, Swords R . Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2016; 31(2):272-281. PMC: 5292675. DOI: 10.1038/leu.2016.275. View

Yan H, Parsons D, Jin G, McLendon R, Rasheed B, Yuan W . IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-73. PMC: 2820383. DOI: 10.1056/NEJMoa0808710. View

Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D . Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 2017; 133(4):629-644. DOI: 10.1007/s00401-017-1677-y. View

10.

Zheng B, Yao Y, Liu Z, Deng L, Anglin J, Jiang H . Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. ACS Med Chem Lett. 2013; 4(6):542-546. PMC: 3686309. DOI: 10.1021/ml400036z. View

11.

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

12.

Losman J, Looper R, Koivunen P, Lee S, Schneider R, McMahon C . (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013; 339(6127):1621-5. PMC: 3836459. DOI: 10.1126/science.1231677. View

13.

Green A, Beer P . Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010; 362(4):369-70. DOI: 10.1056/NEJMc0910063. View

14.

Birendra K, DiNardo C . Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016; 16(8):460-5. PMC: 4983480. DOI: 10.1016/j.clml.2016.04.006. View

15.

Cairns R, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais J . IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012; 119(8):1901-3. PMC: 3293643. DOI: 10.1182/blood-2011-11-391748. View

16.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

17.

Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2010; 465(7300):966. PMC: 3766976. DOI: 10.1038/nature09132. View

18.

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View

19.

Chaturvedi A, Araujo Cruz M, Jyotsana N, Sharma A, Yun H, Gorlich K . Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood. 2013; 122(16):2877-87. DOI: 10.1182/blood-2013-03-491571. View

20.

DiNardo C, Propert K, Loren A, Paietta E, Sun Z, Levine R . Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013; 121(24):4917-24. PMC: 3682342. DOI: 10.1182/blood-2013-03-493197. View